Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Paxil CR, PAXIL (Paroxetine hydrochloride )
Paxil · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| open label treatment | EXPERIMENTAL | On each treatment period, subjects will receive controlled release paroxetine 37.5 milligram (mg) on Day 1. |
| Name | Type | Description |
|---|---|---|
| Paxil CR | DRUG | Paxil CR 37mg tablet manufactures at two different sites |
Key Inclusion: Healthy males or females between 18-65. Body weight 50 kg (110 lbs) or higher, and BMI within the range 19-30 kg/m2. Willing to use acceptable forms of birth control throughout the study. Normal labs and ECG. Key Exclusion: Positive test for drugs or alcohol. Positive for Hepatitis...
Top 20 of 31 competitors
Paxil is a small molecule medicine developed by GSK plc for depressive disorder, a condition within psychiatry. It is also known as Paxil CR and paroxetine hydrochloride. Paxil is investigational in the development stage described here, with clinical work recorded at Phase 1 rather than as an approved product.
Paxil is being studied for depressive disorder. The recorded clinical work in this indication is a Phase 1 bioequivalence study conducted in the United States. Because the development stage listed is Phase 1, Paxil is investigational for depressive disorder and is not described here as an approved treatment.
Paxil is developed by GSK plc, which trades under the ticker GSK. GSK is the company associated with the Paxil program for depressive disorder, including the Phase 1 bioequivalence study of Paxil CR conducted in the United States.
Paxil is in Phase 1 development for depressive disorder. One Phase 1 trial is recorded, and it has completed, with no active trials listed. Paxil is therefore investigational in this program and is not described as FDA approved.
Paxil has been studied in the Phase 1 trial NCT00749359, titled PAXIL CR Bioequivalence Study. That trial enrolled 166 participants in the United States, included adults 18 years and older of all sexes, and used healthy volunteers. It is recorded as completed, and no active trials are listed.
Yes. Paxil is also known as Paxil CR and as paroxetine hydrochloride. Paxil CR refers to the controlled-release form studied in the Phase 1 bioequivalence trial NCT00749359, and paroxetine hydrochloride is the chemical name for the same small molecule developed by GSK plc.